首页> 外文期刊>Naunyn-Schmiedeberg's Archives of Pharmacology >Effective kinetics of schisandrin B on serum/hepatic triglyceride and total cholesterol levels in mice with and without the influence of fenofibrate.
【24h】

Effective kinetics of schisandrin B on serum/hepatic triglyceride and total cholesterol levels in mice with and without the influence of fenofibrate.

机译:五味子乙素B对有或没有非诺贝特影响的小鼠的血清/肝甘油三酸酯和总胆固醇水平的有效动力学。

获取原文
获取原文并翻译 | 示例
           

摘要

Schisandrin B, an active ingredient isolated from the fruit of Schisandra chinensis, increased serum and hepatic triglyceride levels in mice. In the present study, the effective kinetics of schisandrin B on serum/hepatic triglyceride and total cholesterol levels in mice without and with the influence of fenofibrate were investigated. Parameters on hepatic index (the ratio of liver weight to body weight x 100) were also analyzed. Mice were intragastrically treated with schisandrin B at a single dose of 0.2, 0.4, 0.8, or 1.6 g/kg, without or with fenofibrate pretreatment (0.1 g/kg/day for 4 days, p.o.). Twenty-four hours after schisandrin B treatment, serum/hepatic triglyceride and total cholesterol levels were measured. Schisandrin B treatment dose-dependently increased serum and hepatic triglyceride levels as well as hepatic index in mice. In contrast, hepatic total cholesterol levels were decreased in a dose-dependent manner in schisandrin B-treated mice. Data obtained from effective kinetics analysis indicated that the action of schisandrin B on serum triglyceride had a higher specificity than those on hepatic total cholesterol and hepatic index. While fenofibrate pretreatment inhibited the schisandrin B-induced elevation in serum triglyceride levels, it completely abrogated the elevation of hepatic triglyceride levels in schisandrin B-treated mice. The combined treatment with schisandrin B and fenofibrate decreased hepatic total cholesterol level and increased the hepatic index in an additive or semi-additive manner, respectively. In conclusion, the results of effective kinetics analysis indicated that the schisandrin B-induced hypertriglyceridemia was competitively inhibited by fenofibrate. Schisandrin B may offer the prospect of setting up a mouse model of hypertriglyceridemia and fatty liver for screening triglyceride-lowering drug candidates.
机译:从五味子的果实中分离出的有效成分五味子素B可增加小鼠血清和肝甘油三酯水平。在本研究中,研究了五味子乙素B对有和没有非诺贝特影响的小鼠的血清/肝甘油三酸酯和总胆固醇水平的有效动力学。还分析了肝指数的参数(肝重与体重之比×100)。小鼠用五味子乙素B以0.2、0.4、0.8或1.6 g / kg的单次剂量进行胃内治疗,无或无非诺贝特预处理(0.1 g / kg /天,共4天,口服)。五味子乙素B处理后二十四小时,测量血清/肝甘油三酸酯和总胆固醇水平。五味子乙素B剂量依赖性地增加了小鼠的血清和肝甘油三酯水平以及肝指数。相反,在五味子素B处理的小鼠中,肝脏总胆固醇水平呈剂量依赖性降低。从有效动力学分析获得的数据表明,五味子乙素B对血清甘油三酸酯的作用具有比对肝总胆固醇和肝指数更高的特异性。非诺贝特预处理抑制五味子素B诱导的血清甘油三酯水平升高,但完全消除了五味子素B处理的小鼠肝中甘油三酸酯水平的升高。五味子乙素B和非诺贝特的联合治疗分别以累加或半累加的方式降低了肝脏的总胆固醇水平并提高了肝指数。总之,有效动力学分析的结果表明非诺贝特竞争性地抑制了五味子B诱导的高甘油三酯血症。五味子乙可能为建立高甘油三酯血症和脂肪肝的小鼠模型提供前景,以筛选降低甘油三酯的候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号